Lyme disease primary prevention: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Primary prevention of Lyme disease involves reducing exposure to ticks. Scientists have been developing all-natural chemical compounds made from plants that can repel or kill ticks. | Primary prevention of Lyme disease involves reducing exposure to ticks. Scientists have been developing all-natural chemical compounds made from plants that can repel or kill ticks. A Lyme disease vaccine is no longer available. | ||
==Primary Prevention== | ==Primary Prevention== | ||
Revision as of 10:17, 18 August 2015
|
Lyme disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Lyme disease primary prevention On the Web |
|
American Roentgen Ray Society Images of Lyme disease primary prevention |
|
Risk calculators and risk factors for Lyme disease primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Primary prevention of Lyme disease involves reducing exposure to ticks. Scientists have been developing all-natural chemical compounds made from plants that can repel or kill ticks. A Lyme disease vaccine is no longer available.
Primary Prevention
Vaccination
A vaccine, called Lymerix, against a North American strain of the spirochetal bacteria was available from 1998 to 2002. It was produced by GlaxoSmithKline (GSK) and was based on the outer surface protein A (Osp-A) of Borrelia. Osp-A causes the human immune system to create antibodies that attack that protein. When taking it off the market, GSK cited poor sales, need for frequent boosters, the high price of the vaccine, and exclusion of children. Some people believe that the actual reason was that the vaccine was neither safe nor effective. A group of patients who took Lymerix developed arthritis, muscle pain and other troubling symptoms after vaccination. Class-action litigation against GSK followed. Cassidy v. SmithKline Beecham, No. 99-10423 (Ct. Common Pleas, PA state court) (common settlement case).[1]
It was later learned that patients with the genetic allele HLA-DR4 were susceptible to T-cell cross-reactivity between epitopes of OspA and lymphocyte function-associated antigen in these patients causing an autoimmune reaction.[2]
New vaccines are being researched using outer surface protein C (Osp-C) and glycolipoprotein as methods of immunization.[3][4]
References
- ↑ Safety/Efficacy concerns re: Lyme vaccine: LYMErix Controversy LymeInfo.net
- ↑ Willett TA, Meyer AL, Brown EL, Huber BT (2004). "An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope". Proc. Natl. Acad. Sci. U.S.A. 101 (5): 1303–8. doi:10.1073/pnas.0305680101. PMID 14742868.
- ↑ Earnhart CG, Marconi RT (2007). "OspC phylogenetic analyses support the feasibility of a broadly protective polyvalent chimeric Lyme disease vaccine". Clin. Vaccine Immunol. 14 (5): 628–34. doi:10.1128/CVI.00409-06. PMID 17360854.
- ↑ Pozsgay V, Kubler-Kielb J (2007). "Synthesis of an experimental glycolipoprotein vaccine against Lyme disease". Carbohydr. Res. 342 (3–4): 621–6. doi:10.1016/j.carres.2006.11.014. PMID 17182019.